Valuation: H. Lundbeck A/S

Capitalization 4.24TCr 660.61Cr 567.86Cr 531.96Cr 495.83Cr 915.81Cr 59TCr 996.13Cr 6.22TCr 2.4TCr 28TCr 2.48TCr 2.43TCr 1,02700Cr P/E ratio 2025 *
11.3x
P/E ratio 2026 * 10.2x
Enterprise value 5.11TCr 795.82Cr 684.09Cr 640.84Cr 597.31Cr 1.1TCr 72TCr 1.2TCr 7.5TCr 2.89TCr 34TCr 2.99TCr 2.92TCr 1,23700Cr EV / Sales 2025 *
2.08x
EV / Sales 2026 * 1.86x
Free-Float
30.74%
Yield 2025 *
2.8%
Yield 2026 * 3.08%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.63%
1 week+0.81%
Current month+0.81%
1 month-1.45%
3 months+8.06%
6 months+16.61%
Current year+8.37%
More quotes
1 week 43.68
Extreme 43.68
45.12
1 month 42.56
Extreme 42.56
47.16
Current year 27.2
Extreme 27.2
47.78
1 year 27.2
Extreme 27.2
47.78
3 years 25.12
Extreme 25.115
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 01/10/2023
Director of Finance/CFO 48 01/09/2022
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 66 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 59 20/03/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.63%+0.81%+1.96%+70.88% 660.61Cr
-0.68%-8.23%+33.98%+113.90% 9.98TCr
-0.18%-6.33%+61.97%+150.42% 4.72TCr
+3.26%-1.04% - - 2.17TCr
-0.59%+0.31%+11.75%-4.75% 1.04TCr
+0.06%+0.51%-17.63%-6.09% 849.77Cr
+0.49%+2.59%+0.05%+9.13% 824.19Cr
-0.16%+0.77%+20.93%+29.64% 568.34Cr
+0.59%+4.29%-5.37%-0.86% 360.41Cr
-2.63%-2.75%+10.41%+52.04% 349.23Cr
Average +0.08%-1.31%+13.12%+46.03% 2.15TCr
Weighted average by Cap. -0.05%-5.24%+33.27%+99.50%
See all sector performances

Financials

2025 *2026 *
Net sales 2.45TCr 382.03Cr 328.39Cr 307.63Cr 286.74Cr 529.61Cr 34TCr 576.07Cr 3.6TCr 1.39TCr 16TCr 1.43TCr 1.4TCr 59TCr 2.52TCr 392.14Cr 337.08Cr 315.77Cr 294.32Cr 543.62Cr 35TCr 591.3Cr 3.69TCr 1.43TCr 17TCr 1.47TCr 1.44TCr 61TCr
Net income 389.2Cr 61Cr 52Cr 49Cr 45Cr 84Cr 5.46TCr 91Cr 570.98Cr 220.46Cr 2.58TCr 227.52Cr 222.66Cr 9.42TCr 436.43Cr 68Cr 58Cr 55Cr 51Cr 94Cr 6.12TCr 102.5Cr 640.26Cr 247.21Cr 2.89TCr 255.13Cr 249.68Cr 11TCr
Net Debt 868.11Cr 135.21Cr 116.23Cr 108.88Cr 101.49Cr 187.45Cr 12TCr 203.89Cr 1.27TCr 491.74Cr 5.75TCr 507.48Cr 496.65Cr 21TCr 447.2Cr 70Cr 60Cr 56Cr 52Cr 97Cr 6.27TCr 105.03Cr 656.06Cr 253.32Cr 2.96TCr 261.43Cr 255.85Cr 11TCr
More financial data * Estimated data
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,700
More about the company
Date Price Change Volume
05/25/05 44.78 kr +0.63% 2,75,475
04/25/04 44.50 kr +1.09% 2,28,263
03/25/03 44.02 kr -0.68% 3,32,435
02/25/02 44.32 kr +1.23% 2,94,344
01/25/01 43.78 kr -1.44% 5,78,739

Delayed Quote Nasdaq Copenhagen, December 05, 2025 at 09:50 pm IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
44.78DKK
Average target price
48.59DKK
Spread / Average Target
+8.51%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock